Clinical trial

Optimizing the Use of Aspirin for the Prevention of Preeclampsia

NCT07665853

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Discontinuation of Acetylsalicilic acid 150 mg/day at 24-28 weeks of gestation Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Optimizing the Use of Aspirin for the Prevention of Preeclampsia

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-07-01

PhasePHASE3

Conditions

Preeclampsiaverified · MONDO: preeclampsia

Interventions

Discontinuation of Acetylsalicilic acid 150 mg/day at 24-28 weeks of gestationDRUG

Sponsors & collaborators

Hospital Universitari Vall d'Hebron Research Institutelead sponsor

Fetal Medicine Foundationcollaborator

Mapped research locations

BarcelonaSpain3 LondonUnited Kingdom2 ViennaAustria2 MadridSpain1 SofiaBulgaria1 A CoruñaSpain1 AlicanteSpain1 GranadaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07665853 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.